Want to see HK:0911 full AI Analyst Report?
0911 Stock Chart & Stats
HK$0.28
-HK$0.03(-8.77%)
At close: 4:00 PM EST
HK$0.28
-HK$0.03(-8.77%)
Day’s Range― - ―
52-Week RangeHK$0.21 - HK$1.40
Previous CloseN/A
Volume500.00
Average Volume (3M)199.38K
Market Cap
HK$108.44M
Enterprise ValueHK$57.65M
Total Cash (Recent Filing)HK$61.38M
Total Debt (Recent Filing)HK$424.00K
Price to Earnings (P/E)30.5
Beta-0.23
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding169,445,000
10 Day Avg. Volume241,207
30 Day Avg. Volume199,376
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.12
Price to Sales (P/S)0.07
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base provide durable financial flexibility, reducing refinancing and bankruptcy risk. This stability supports capital allocation for R&D, regulatory milestones or opportunistic M&A without pressuring cash flows, sustaining operations through industry cycles.
Strengthened Cash GenerationA material improvement in operating and free cash flow indicates the business can self-fund activities and absorb near-term shocks. Consistent positive cash generation enhances reinvestment capacity and lowers dependence on external financing, improving long-term operational resilience.
Revenue Rebound And Profitability ReturnA sharp revenue recovery and return to net profitability point to regained demand or improved commercialization execution. Sustained top-line recovery validates the business model and provides a base to scale margins and margins-enhancing initiatives over the medium term, if maintained.
Bears Say
Very Thin Profit MarginsExtremely low gross and net margins constrain the company's ability to convert revenue into meaningful returns. Such compressed margins leave little room to absorb cost inflation, pricing pressure or higher SG&A, limiting sustainable profitability and resilience to industry headwinds.
Fragile Recovery And Historical VolatilityThe recent turnaround follows multi-year losses and cash burn, indicating the recovery may be fragile. Historical volatility suggests earnings and cash flows can swing materially, raising execution risk for sustained growth and creating uncertainty around repeatable operational performance.
Low Return On EquityModest ROE implies the company generates limited profit from its capital base, signaling constrained capital efficiency. Low returns can hamper long-term shareholder value creation and limit internal funding for growth initiatives unless profitability and asset productivity materially improve.
Qianhai Health Holdings Ltd. News
0911 FAQ
What was Qianhai Health Holdings Ltd.’s price range in the past 12 months?
Qianhai Health Holdings Ltd. lowest stock price was HK$0.20 and its highest was HK$1.40 in the past 12 months.
What is Qianhai Health Holdings Ltd.’s market cap?
Qianhai Health Holdings Ltd.’s market cap is HK$108.44M.
When is Qianhai Health Holdings Ltd.’s upcoming earnings report date?
Qianhai Health Holdings Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 54 days.
How were Qianhai Health Holdings Ltd.’s earnings last quarter?
Qianhai Health Holdings Ltd. released its earnings results on Mar 18, 2026. The company reported HK$0.007 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.007.
Is Qianhai Health Holdings Ltd. overvalued?
According to Wall Street analysts Qianhai Health Holdings Ltd.’s price is currently Overvalued.
Does Qianhai Health Holdings Ltd. pay dividends?
Qianhai Health Holdings Ltd. pays a Notavailable dividend of HK$0.1 which represents an annual dividend yield of N/A. See more information on Qianhai Health Holdings Ltd. dividends here
What is Qianhai Health Holdings Ltd.’s EPS estimate?
Qianhai Health Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qianhai Health Holdings Ltd. have?
Qianhai Health Holdings Ltd. has 169,445,000 shares outstanding.
What happened to Qianhai Health Holdings Ltd.’s price movement after its last earnings report?
Qianhai Health Holdings Ltd. reported an EPS of HK$0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Qianhai Health Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:0911
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qianhai Health Holdings Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.52%
12-Months-Change
Fundamentals
Return on Equity
0.91%
Trailing 12-Months
Asset Growth
0.26%
Trailing 12-Months
Company Description
Qianhai Health Holdings Ltd.
Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health-Care Products and Electronic Component Products. The Health-Care Products segment supplies a range of items, including Chinese herbal medicines, various skincare and wellness products, and American ginseng, catering to both wholesale and retail clients. Concurrently, the Electronic Component Products division deals in items such as central processing units (CPUs) and semiconductors. Beyond these primary sales, the company also engages in the trading of both its health-care and electronic component offerings, alongside a money lending business. Established in 1989, the company underwent a name change in September 2016 from its previous identity, Hang Fat Ginseng Holdings Company Limited. It is headquartered in Sheung Wan, Hong Kong, and operates as a subsidiary of Explorer Rosy Limited.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Jacobson Pharma Corporation Limited
―